Apolipoprotein E knockout models

Current Pharmaceutical Design

Volumn 14, Issue 4, 2008, Pages 338-351

  Kolovou, Genovefa ^a   Anagnostopoulou, Katherine ^c   Mikhailidis, Dimitri P ^b   Cokkinos, Dennis V ^c  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NONE

Author keywords

Apolipoprotein E; Atherosclerosis; Knock out

Indexed keywords

ABC TRANSPORTER A1; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR; ANTIDIABETIC AGENT; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CHOLESTEROL ACYLTRANSFERASE; CURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FC RECEPTOR; FRACTALKINE; GLYCOSPHINGOLIPID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIVE OIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN SYNTHASE; RETINOID X RECEPTOR; SCAVENGER RECEPTOR BI; SELECTIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; XANTHINE OXIDASE;

ALZHEIMER DISEASE; ANGIOGENESIS; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CATABOLISM; CELL THERAPY; CHOLESTEROL DIET; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG MECHANISM; ENTEROHEPATIC CIRCULATION; GENE THERAPY; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; KNOCKOUT MOUSE; LIPID DIET; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; ANIMAL; GENETICS; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; PROTEIN BINDING;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; MICE; MICE, KNOCKOUT; PROTEIN BINDING;

EID: 42049093461     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783497769     Document Type: Review

References (255)

1. Active Ageing. A policy Framework. World Health Organization. Geneva, Switzerland: Document. WHO/NMH/NPH/02.8.
2. Acton RT, Go RC, Roseman JM. Genetics and cardiovascular disease. Ethn Dis 2004; 14: S2-8-16.
3. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57: 791-804.
4. Daugherty A, Rateri DL. Development of experimental designs for atherosclerosis studies in mice. Methods 2005; 36: 129-38.
5. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-5.
6. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-71.
7. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-53.
8. van Ree JH, van den Broek WJ, Dahlmans VE, Groot PH, Vidgeon-Hart M, Frants RR, et al. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 1994; 111: 25-37.
9. Seitz A, Gourevitch D, Zhang XM, Clark L, Chen P, Kragol M, et al. Sense and antisense transcripts of the apolipoprotein E gene in normal and ApoE knockout mice, their expression after spinal cord injury and corresponding human transcripts. Hum Mol Genet 2005; 14: 2661-70.
10. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioseler Thromb 1994; 14:141-7.
11. Napoli C, Palinski W, Di Minno G, D'Armiento FP. Determination of atherogenesis in apolipoprotein E-knockout mice. Nutr Metab Cardiovasc Dis 2000; 10: 209-15.
12. Yamashita T, Kawashima S, Ozaki M, Namiki M, Shinohora M, Inoue N, et al. In vivo angiographic detection of vascular lesions in apolipoprotein E-knockout mice using a synchrotron radiation microangiography system. Cire J 2002; 66: 1057-9.
13. Tamminen M, Mottino G, Qiao JH, Breslow JL, Frank JS. Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999;, 19: 847-53.
14. Tse J, Martin-McNaulty B, Halks-Miller M, Kauser K, DelVecchio V, Vergona R, et al. Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 beta-estradiol. Atherosclerosis 1999; 144: 303-13.
15. Smith JD, Breslow JL. The emergence of mouse models of atherosclerosis and their relevance to clinical research. J Intern Med 1997; 242: 99-109.
16. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21.
17. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vase Biol 1996; 16:1250-5.
18. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
19. Bretsky P, Guralnik JM, Laurier L, Albert M, Seeman TE. The role of APOE-cpsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 2003; 60: 1077-81.
20. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Apolipoprotein epsilon4 homozygosity and essential hypertension. South Med J 2004; 97: 1022.
21. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257: 2518-21.
22. Kolovou G, Yiannakouris N, Hatzivassiliou M, Malakos J, Daskalova D, Hatzigeorgiou G, et al. Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients with coronary artery disease. Curr Med Res Opin 2002; 18: 118-24.
23. Kolovou GD, Anagnostopoulou KK, Mikhailidis DP, Panagiotakos DB, Pilatis ND, Cariolou MA, et al. Association of apolipoprotein E genotype with early onset of coronary heart disease in Greek men. Angiology 2005; 56: 663-70.
24. Bailleul S, Couderc R, Landais V, Lefevre G, Raichvarg D, Etienne J. Direct phenotyping of human apolipoprotein E in plasma: application to population frequency distribution in Paris (France). Hum Hered 1993; 43: 159-65.
25. Rea IM, Me Dowell I, McMaster D, Smye M, Stout R, Evans A. Apolipoprotein E alleles in nonagenarian subjects in the Belfast Elderly Longitudinal Free-living Ageing Study (BELFAST). Mech Ageing Dev 2001; 122: 1367-72.
26. Kolovou GD, Anagnostonolilou KK. Apolipoprotein E polymorphism, age and coronary heart disease. Ageing Res Rev 2007; 6: 94-108.
27. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994; 6: 29-32.
28. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995; 91: 265-9.
29. Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet 1987; 27: 567-82.
30. Pablos-Mendez A, Mayeux R, Ngai C, Shea S, Berglund L. Association of apo E polymorphism with plasma lipid levels in a multi-ethnic elderly population. Arterioscler Thromb Vase Biol 1997; 17: 3534-41.
31. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidermol 1990; 131: 32-47.
32. Raiha I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol 1997; 17: 1224-32.
33. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992; 267: 70-6.
34. Hamanaka H, Katoh-Fukui Y, Suzuki K, Kobayashi M, Suzuki R, Motegi Y, et al. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum Mol Genet 2000; 9: 353-61.
35. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997; 272: 17972-80.
36. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoc*2. J Clin Invest 1998; 102: 130-5.
37. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999; 103: 1579-86.
38. Choi J, Forster MJ, McDonald SR, Weintraub ST, Carroll CA, Gracy RW. Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimees disease. Free Radic Biol Med 2004; 36: 1155-62.
39. Crisby M, Rahman SM, Sylven C, Winblad B, Schultzbeig M. Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke. Neurosci Lett 2004; 369: 87-92.
40. Behr-Roussel D, Darblade B, Oudot A, Compagnie S, Bernabe J, Alexandre L, et al. Erectile dysfunction in hypercholesterotemic atherosclerotic apolipoprotein E knockout mice. J Sex Med 2006; 3: 596-603.
41. Ezzahiri R, Stassen FR, Kurvers HA, van Pul MM, Kitslaar PJ, Bruggeman CA, Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur J Vasc Endovasc Surg 2003; 26: 88-95.
42. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23-8.
43. Liuba P, Karnani P, Pesonen E, Forslid A, Johansson L, Persson K, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000; 102: 1039-44.
44. Vliegen I, Stassen F, Grauls G, Blok R, Bruggeman C. MCMV infection increases early T-lymphocyte influx in atherosclerotic lesions in apoE knockout mice. J Clin Virol 2002; 25(Suppl 2): S159-71.
45. Vliegen I, Duijvestijn A, Grauls G, Herrigreen S, Bruggeman C, Stassen F. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect 2004; 6: 17-24.
46. Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: 1016-23.
47. Tous M, Ferre N, Camps J, Riu F, Joven J. Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol Cell Biochem 2005; 268: 53-8.
48. Ali ZA, Alp NJ, Lupton H, Arnold N, Bannister T, Hu Y, et al. Increased in-stent stenosis in ApoE knockout mice: insights from a novel mouse model of balloon angioplasty and stenting. Arterioscler Thromb Vasc Biol 2007; 27: 833-40.
49. Matter CM, Ma L, von Lukowicz T, Lohmann C, Zhang D, Kilic U, et al. Increased balloon-induced inflammation, proliferation, and neointima formation in apolipoprotein E (ApoE) knockout mice. Stroke 2006; 37: 2625-32.
50. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30.
51. Auger A, Truong TQ, Rhainds D, Lapointe J, Letarte F, Brissette L. Low and high density lipoprotein metabolism in primary cultures of hepatic cells from normal and apolipoprotein E knockout mice. Eur J Biochem 2001; 268: 2322-30.
52. Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun 1972; 46:1493-8.
53. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211-28.
54. Furbee JW Jr, Sawyer JK, Parks JS. Lecithin:cholestcrol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 2002; 277: 3511-9.
55. Chang TY, Chang CC, Cheng D. Acyl-coenzyme A: cholesterol acyltransferase. Annu Rev Biochem 1997; 66: 613-28.
56. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314: 488-500.
57. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in athercsclerosis. Annu Rev Biochem 1983; 52: 223-61.
58. Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci 1991; 12: 194-9.
59. Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase 1. J Clin Invest 2000; 105: 711-9.
60. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2604-9.
61. Hakamata H, Sakaguchi H, Zhang C, Sakashita N, Suzuki H, Miyazaki A, et al. The very low-and intermediate-density lipoprotein fraction isolated from apolipoprotein E-knockout mice transforms macrophages to foam cells through art apolipoprotein E-indapendent pathway. Biochemistry 1998; 37: 13720-7.
62. Zhang C, Akira M, Hideki H, Hisashi S, Seikoh H. Very low and intermediate density tipoprotein fractions from apolipoprotein E gene-knockout mice induce cholesteryl ester accumulation in J774 macrophages. Chin Med J (Engl) 1999; 112: 543-5.
63. Westerterp M, de Haan W, Berbee JF, Havekes LM, Rensen PC. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 2006; 47: 1203-11.
64. Irwin D, O'Looney PA, Quinet E, Vahouny GV. Application of SDS gradient polyacrylamide slab gel electrophoresis to analysis of apolipoprotein mass and radioactivity of rat lipoproteins. Atherosclerosis 1984; 53: 163-72.
65. Rudel LL, Kelley K, Sawyer JK, Shah R, Wilson MD. Dietary monounsaturated fatty acids promote aortic atherosclerosis in LDL receptor-null, human ApoB100-overexpressing transgenic mice. Arterioscler Thromb Vase Biol 1998; 19: 1819-27.
66. Parks JS, Kaduck-Sawyer J, Bullock BC, Rudel LL. Effect of dietary fish oil on coronary artery and aortic atherosclerosis in African green monkeys. Arteriosclerosis 1990; 10: 1102-12.
67. Parks JS, Wilson MD, Johnson FL, Rudel LL. Fish oil decreases hepatic cholesteryl ester secretion but not apoB secretion in African green monkeys. J Lipid Res 1989; 30: 1535-44.
68. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, Wilson MD, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000; 106: 1501-10.
69. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990; 31: 859-69.
70. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
71. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, et al. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest 1997; 99: 2858-66.
72. Boisvert WA, Black AS, Curtiss LK. ApoAl reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 525-30.
73. Voyiaziakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL, Huang LS. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res 1998; 39: 313-21.
74. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000; 20: 721-7.
75. Garner B, Priestman DA, Stocker R, Harvey DJ, Butters TD, Platt FM. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res 2002; 43: 205-14.
76. Hakansson P, Andersson I, Nystrom S, Lofgren L, Amrot LF, Li H. Ontogenetic development and spatial distribution of the ileal apical sodium-dependent bile acid transporter and the ileal lipid-binding protein in apoE knockout and C57BL/6 mice. Scand J Gastroenterol 2002; 37: 1089-96.
77. Sehayek E, Shefer S, Nguyen LB, Ono JG, Merkel M, Breslow JL. Apolipoprotein E regulates dietary cholesterol absorption and biliary cholesterol excretion: studies in C57BL/6 apolipoprotein E knockout mice. Proc Natl Acad Sci USA 2000; 97: 3433-7.
78. Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor? Am J Epidemiol 1994; 140: 669-82.
79. Callaghan FJ, Geddes LA, Babbs CF, Bourland JD. Relationship between pulse-wave velocity and arterial elasticity. Med Biol Eng Comput 1986; 24: 248-54.
80. Wang YX, Halks-Miller M, Vergona R, Sullivan ME, Fitch R, Mallari C, et al. Increased aortic stiffness assessed by pulse wave velocity in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 2000; 278: H428-34.
81. Hartley CJ, Reddy AK, Madala S, Martin-McNulty B, Vergona R, Sullivan ME, et al. Hemodynamic changes in apolipoprotein E-knockout mice. Am J Physiol Heart Circ Physiol 2000; 279: H2326-34.
82. Vincelette J, Martin-McNulty B, Vergona R, Sullivan ME, Wang YX. Reduced cardiac functional reserve in apolipoprotein E knockout mice. Transl Res 2006; 148: 30-6.
83. Yang R, Powell-Braxton L, Ogaoawara AK, Dybdal N, Bunting S, Ohneda O, et al. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 1999; 19: 2762-8.
84. Lemaitre V, O'Byme TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE knockout mice expressing human matrix metallo-proteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001; 107: 1227-34.
85. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
86. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
87. Hu L, Boesten LS, May P, Herz J, Bovenschen N, Huisman MV, et al. Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice. Arterioscler Thromb Vasc Biol 2006; 26: 2710-5.
88. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2002; 22: 788-92.
89. Jones GT, Jiang F, McCormick SP, Dusting GJ. Elastic lamina defects are an early feature of aortic lesions in the apolipoprotein E knockout mouse. J Vasc Res 2005; 42: 237-46.
90. Xu F, Ji J, Li L, Chen R, Hu WC. Adventitial fibroblasts are activated in the early stages of atherosclerosis in the apolipoprotein E knockout mouse. Biochem Biophys Res Commun 2007; 352: 681-8.
91. Shor A, Phillips JI, Ong G, Thomas BJ, Taylor-Robinson D. Chlamydia pneumoniae in atheroma: consideration of criteria for causality. J Clin Pathol 1998; 51: 812-7.
92. Poston RN, Johnson-Tidey RR. Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis. Am J Pathol 1996; 149: 73-80.
93. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Cite Res 1999; 85: 199-207.
94. Larsen E, Celi A, Gilbert GE, Erban JK, Bonfanti R, Wagner DD, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59: 305-12.
95. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-4.
96. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992; 258: 964-9.
97. Carter AM, Anagnostopoulou K, Mansfield MW, Grant PJ, Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease. J Thromb Haemost 2003; 1: 1718-23.
98. Bourdillon MC, Randon J, Barek L, Zibara K, Covacho C, Poston RN, et al. Reduced atherosclerotic lesion size in p-selectin deficient apolipoprotein e-knockout mice fed a ebow but not a fat diet. J Biomed Biotechnol 2006; 2006: 49193.
99. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchier EP, Bullard DC, et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vase Biol 1997; 17: 1517-20.
100. Reselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression. Arterioscler Thromb Vase Biol 1996; 16: 1013-8.
101. Knowles JW, Maeda N. Genetic modifiers ot atherosclerosis in mice. Arterioscler Thromb Vase Biol 2000; 20: 2336-45.
102. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol 1994; 144: 952-61.
103. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 1997; 99: 1037-43.
104. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner DD. The combined role of P-and E-selectins in atherosclerosis. J Clin Invest 1998; 102: 145-52.
105. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101: 2290-5.
106. Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca. G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. Arterioscler Thromb Vase Biol 2000; 20: 2630-5.
107. Manka D, Collins RG, Ley K, Beaudet AL, Sarembock IJ. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 2001; 103: 1000-5.
108. Manka D, Forlow SB, Sanders JM, Hurwitz D, Bennett DK, Green SA, et al. Critical role of platelet P-selectin in the response to arterial injury in apolipoprotein-E-deficient mice. Arterioscler Thromb Vase Biol 2004; 24: 1124-9.
109. Kitagawa K, Matsumoto M, Sasaki T, Hashimoto H, Kubawara K, Ohtsuki T, et al. Involvement of ICAM-1 in the progression of atherosclerosis in APOE-knockout mice. Atherosclerosis 2002; 160: 305-10.
110. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988; 57: 505-18.
111. Jovinge S, Hamsten A, Tornvall P, Proudler A, Bavenholm P, Ericsson CG, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998; 47: 113-8.
112. Schleef RR, Bevilacqua MP, Sawdey M, Gimorone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-803.
113. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25.
114. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscier Thromb Vase Biol 2004; 24: 2137-42.
115. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-40.
116. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
117. Schonbeck U, Sukbova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-91.
118. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003; 108: 3017-23.
119. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-23.
120. Yu H, Zhang W, Yancey PG, Koury MJ, Zhang Y, Fazio S, et al. Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice. Arterioscler Thromb Vase Biol 2006; 26: 150-6.
121. Karackattu SL, Trigatti B, Krieger M. Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dysfunction and extends lifespan in SR-BI/apolipoprotein E double knockout mice. Arterioscler Thromb Vase Biol 2006; 26: 548-54.
122. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vase Biol 2001; 21: 1876-90.
123. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4-T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993; 90: 10188-92.
124. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo B, Cheroutre H, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-71.
125. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vase Biol 1999; 19: 611-6.
126. Lee TS, Yen HC, Pan CC, Chair LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vase Biol 1999; 19: 734-42.
127. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-73.
128. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, et al. Reduced atherosclerosis in interteukin-18 deficient apolipoprotein E-knockout mice. Cardiovase Res 2003; 59: 234-40.
129. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-8.
130. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/-mice. Am J Pathol 2000; 157: 1819-24.
131. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-8.
132. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-30.
133. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages, J Immunol 1996; 157: 4159-65.
134. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999; 5: 189-96.
135. Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van der Ende A, et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997; 89(8): 2701-5.
136. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
137. Von Der Thusen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/-mice. FASEB J 2001; 15: 2730-2.
138. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003; 9: 10-7.
139. Namiki M, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N, et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21-9.
140. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
141. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanowa S, Lee EJ, et al Decreased atherosclerotic lesion formation in CX3CR1/ apolipoprotein E double knockout mice. Circulation 2003; 107: 1009-16.
142. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
143. Mcnczak Y, Trudel M, Lamph WW, Miller WH Jr. Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood 1997; 90: 3345-55.
144. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
145. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001; 98: 2610-5.
146. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Callego-Delgado J, Sanjuan G, et al. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res 2006; 99: 1188-96.
147. Hu W, Polinsky P, Sadoun E, Rosenfeld ME, Schwartz SM. Atherosclerotic lesions in the common coronary arteries of ApoE knockout mice. Cardiovasc Pathol 2005; 14: 120-5.
148. Chappell DA, Medh JD. Receptor-mediated mechanisms of lipoprotein remnant catabolism. Prog Lipid Res 1998; 37: 393-422.
149. Santamarina-Fojo S, Dugi KA. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipidol 1994; 5: 117-25.
150. Yagyu H, Ishibashi S, Chen Z, Osuga J, Okazaki M, Perrey S, et al. Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. J Lipid Res 1999; 40: 1677-85.
151. O'Brien KD, Gordon D, Deeb S, Ferguson M, Chait A. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J Clin Invest 1992; 89: 1544-50.
152. Babaev VR, Fazio S, Gleaves LA, Carter KJ, Semenkovich CF, Linton MF. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest 1999; 103: 1697-705.
153. Wilson K, Fry GL, Chappell DA, Sigmund CD, Medb JD. Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice. Arterioseler Thromb Vasc Biol 2001; 21: 1809-15.
154. Zuckerman SH, Kauffman RF, Evans GF. Peroxisome proliferator-activated receptor alpha gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids 2002; 37: 487-94.
155. Peters W, Cham IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein 1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 2001; 12: 175-80.
156. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2002; 22: 554-9.
157. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002; 106: 2700-6.
158. Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circulation 2000; 102: III90-4.
159. Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV. Tangier disease four decades of research: a reflection of the importance of HDL. Curr Med Chem 2006; 13: 771-82.
160. Kolovou GD, Cokkinos DV. Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. Curr Med Res Opin 2002; 18: 265-8.
161. Glomset JA. The plasma lecithins:cholesterel acyltransferase reaction. J Lipid Res 1968; 9: 155-167.
162. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104: R25-31.
163. Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najb-Fruchart J, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA 2002; 99: 407-12.
164. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
165. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules:
166. Radomski MW, Palmer RM, Moncada S. Modulation of platelet aggregation by an L-arginine-nitric oxide pathway. Trends Pharmacol Sci 1991; 12: 87-8.
167. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17: 2479-88.
168. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein L'endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104: 448-54.
169. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075-95.
170. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-8.
171. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-9.
172. Li Z, Li L, Zielke HR, Xiao R, Crow MT, Stetler-Stevenson WG, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-8.
173. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-31.
174. Henney AM, Wakeley PR, Daveis MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8.
175. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996; 93: 9748-53.
176. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999; 99: 3103-9.
177. Katsuda S, Okada Y, Minamoto T, Oda Y, Matsui Y, Nakanishi I. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb 1992; 12: 494-502.
178. Kolovou G. The treatment of coronary heart disease: an update. Part 3: Statins beyond cholesterol lowering. Curr Med Res Opin 2001; 17: 34-7.
179. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-6.
180. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17527-35.
181. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105: 393-6.
182. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002; 105: 530-6.
183. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31-8.
184. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-54.
185. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G.-Inhibition of diet-induced atheroscierosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004; 110: 3062-7.
186. Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2001; 38: 395-405.
187. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44: 579-87.
188. Yamashita T, Oda E, Sano T, Yamashita T, Ijiru Y, Giddings JC, et al. Varying the ratio of dietary n-6/n-3 polyunsaturated fatty acid alters the tendency to thrombosis and progress of atherosclerosis in apoE-/-LDLR-/-double knockout mouse. Thromb Res 2005; 116: 393-401.
189. Wang HH, Hung TM, Wei J, Chiang AN. Fish oil increases anti-oxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice. Cardiovasc Res 2004; 61: 169-76.
190. Carluccio MA, Siculella L, Ancora MA, Massaro M, Scoditti, E, Storelli C, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003; 23: 622-9.
191. Acin S, Navarro MA, Camicer R, Arbones-Mainar JM, Guzman MA, Amal C, et al. Dietary cholesterol suppresses the ability of olive oil to delay the development of atherosclerotic lesions in apolipoprotein E knockout mice. Athersclerosis 2005; 182: 17-28.
192. Acin S, Navarro MA, Perona JS, Arbones-Mainar JM, Surra JC, Guzman MA, et al. Olive oil preparation determines the atherosclerotic protection in apolipoprotein E knockout mice. J Nutr Biochem 2007; 18: 418-24.
193. Jouany JP, Lassalas B, Doreau M, Glasser F. Dynamic features of the rumen metabolism of linoleic acid, linolenic acid and linseed oil measured in vitro. Lipids 2007,42: 351-60.
194. Fan YY, Ramos KS, Chapkin RS. Dietary gamma-linolenic acid suppresses aortic smooth muscle cell proliferation and modifies atherosclerotic lesions in apolipoprotein E knockout mice. J Nutr 2001; 131: 1675-81.
195. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol 2003; 23: 97-103.
196. Handy DE, Scolaro J, Chen J, Huang P, Loscalzo J. L-arginine increases plasma homocysteine in apoE-/-/iNOS-/- double knockout mice. Cell Mol Biol (Noisy-le-grand) 2004; 50: 903-9.
197. Rahman SM, Van Dam AM, Schultzberg M, Crisby M. High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice. J Neuroimmunol 2005; 169: 59-67.
198. Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, et al. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005; 56: 627-35.
199. Schroder K, Vecchione C, Jung O, Schreiber JG, Shiri-Sverdlov R, van Gorp PJ, et al. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed a Western-type diet. Free Radic Biol Med 2006; 41: 1353-60.
200. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
201. Diaz MN, Frei B, Vita JA, Keaney JF, Jr. Antioxidants and athesclerotic heart disease. N Engl J Med 1997; 337: 408-16.
202. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998; 4: 1189-92.
203. Thomas SR, Leichtweis SB, Pettersson K, Croft KD, Mori TA, Brown AJ, et al. Dietary cosupplementation with vitamin E and coenzyme (Q0) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 2001; 21: 585-93.
204. Peluzio MC, Miguel E Jr, Drumond TC, Cesar CC, Santiago HC, Teixeira MM, et al. Monocyte chemoattractant protein-1 involvement in the alpha-tocopherol-induced reduction of atherosclerotic lesions in apolipoprotein E knockout mice. Br J Nutr 2003; 90: 3-11.
205. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005; 111: 1422-30.
206. Naoum JJ, Zhang S, Woodside KJ, Song W, Guo QBelalcazar LM, et al. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and sinivastatin. Surgery 2004; 136: 323-8.
207. Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol 1999; 10: 589-97.
208. Sawayama Y, Shimizu C, Maeda N, Tatsukawa K, Kinukawa N, Koyanagi S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002; 39: 610-6.
209. Choy K, Beck K, Pug FY, Wu BJ, Leichtweis SB, Thomas SR, et al. Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 1684-90.
210. Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63.
211. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006; 22: 511-28.
212. Davis HR, Jr., Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001; 21: 2032-8.
213. Ueshima K, Akihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull 2005; 28: 247-52.
214. Ksander GM, deJesus R, Yuan A, Fink C, Moskal M, Carlson E, et al. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J Med Chem 2001; 44: 4677-87.
215. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003; 44: 1887-901.
216. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005; 12: 1931-45.
217. Jandeleit-Dahm K, Lassila M, Davis BJ, Candido R, Johnston CI, Allen TJ, et al. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J Hypertens 2005; 23: 2071-82.
218. Chen J, Li D, Schaefer RF, Mehta JL. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovase Pharmacol 2004; 44: 446-52.
219. de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopcs in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107-15.
220. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 2007; 195: 17-22.
221. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-8.
222. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Clefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects tmated with troglitazone. N Engl J Med 1994; 331: 1188-93.
223. Chen Z, Ishibashi S, Perrey S, Osuga Ji, Gotoda T, Kitamine T, et al. Troghtazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21: 372-7.
224. Jawien J, Csanyi G, Gajda M, Mateuszuk L, Lomnicka M, Korbut R, et al. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Eur J Pharmacol 2007; 556. 129-35.
225. Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 865-70.
226. Kloog Y, Cox AD, Sinensky M. Concepts in Ras-directed therapy. Expert Opin Investig Drugs 1999; 8: 2121-40.
227. George J, Afek A, Keren P, Herz I, Goldberg I, Haklai R, et al. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation 2002; 105: 2416-22.
228. Chiwata T, Aragane K, Fujinami K, Kojima K, Ishibashi S, Yamada N, et al. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Br J Pharmacol 2001; 133: 1005-12.
229. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001; 59: 1324-32.
230. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147-53.
231. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AX, Allen TJ, et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16: 163-73.
232. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyclin of retained low-density lipoprotein. Proposed role for arterial-Wall sphingomyclinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98: 1455-64.
233. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20: 2614-8.
234. Park TS, Panek RL, Mueller SB, Rosebury WS, Robertson AW, Kindt EK, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110: 3465-71.
235. Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 2007; 16: 283-9.
236. Glaros EN, Kim WS, Wu BJ, Suarna C, Qnn CM, Rye KA, et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 2007; 73: 1340-6.
237. Yamashita T, Kawashima S, Ozaki M, Namiki M, Inoue N, Hirata K, et al. Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler Thromb Vasc Biol 2002; 22: 969-74.
238. Sternitzky R, Seige K. Clinical investigation of the effects of pentoxifylline in patients with severe peripheral occlusive vascular disease. Curr Med Res Opin 1985; 9: 602-10.
239. Apollonio A, Castignani P, Magrini L, Angeletti R. Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. J Int Med Res 1989; 17: 28-35.
240. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001; 104: 197-202.
241. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481-6.
242. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 2003; 35: 3136-8.
243. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001; 103: 2096-101.
244. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
245. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9: 702-12.
246. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003; 107: 461-8.
247. Alobaid N, Alnaeb ME, Seifalian AM, Mikhailidis DP, Hamilton G. Endothelial progenitor cells and their potential clinical applications in peripheral arterial disease. Endothelium 2005; 12; 243-50.
248. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Qyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
249. George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vase Biol 2003; 23: e57-60.
250. George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A, et al. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 2004; 25: 1003-8.
251. Wollert KC, Drexler H. Clinica: applications of stem cells for the heart. Circ Res 2005; 96: 151-63.
252. George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J, et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 2636-41.
253. Guo J, Van Eck M, Twisk J, Maeda N, Benson GM, Groot PH, et al. Transplantation of monocyte CC-chemokine receptor 2-deficient bone marrow into ApoE3-Leiden mice inhibits athero-genesis. Arterioscler Thromb Vasc Biol 2003; 23: 447-53.
254. Guo J, de Waard V, Van Eck M, Hildebrand RB, van Wanrooij EJ, Kuiper J, et al. Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Arterioscler Thromb Vasc Biol 2005; 25: 1014-9.
255. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108: 457-63.